The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Deloitte notes that many companies are trying to capture a share of the $200 billion GLP-1 drug market. Beyond obesity, potential indications for these drugs include sleep apnea, addiction ...
CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...
Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...
Donald Trump and his advisers are about to launch a consequential battle against unhealthy food producers and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback